Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Provided By GlobeNewswire
Last update: Aug 8, 2024
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial
Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024
Read more at globenewswire.com
